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A B S T R A C T
Purpose
To determine whether epidermal growth factor receptor (EGFR) expression in non–small-cell
lung cancer (NSCLC) is modulated by chemotherapy and to assess the agreement of EGFR
status between mediastinal nodes and the primary tumor after chemotherapy.
Patients and Methods
Patients with NSCLC stage IIIa/b pN2/3 confirmed by mediastinoscopy or mediastinostomy
were treated with at least three cycles of chemotherapy before undergoing surgery. EGFR
expression was evaluated on mediastinal nodes at the time of initial diagnosis and on both
the primary tumor and residual metastatic nodes after treatment.
Results
EGFR expression determined on 138 of 164 patients who underwent mediastinoscopy or
mediastinostomy was 0 (22 patients), 1 (27 patients), 2 (28 patients), and 3 (61
patients). Fifty-four patients of 164 received chemotherapy followed by surgery. Of the 89 of
138 patients with EGFR score of 2/3 at the time of diagnosis, 34 patients underwent
surgery after induction chemotherapy. None changed to zero EGFR immunoreactivity, with
29 patients (88%) maintaining a score of 2/3. Of the 22 of 138 patients with no EGFR
expression at the time of diagnosis, six underwent surgical resection after induction
chemotherapy. Of these six patients, four changed their EGFR expression from an EGFR
score of 0 to 2/3. After treatment, the agreement of EGFR status between tumor and
nodes in the subgroup of patients with EGFR score 2/3 was 89% to 92%.
Conclusion
Our data suggest a very good agreement of EGFR status before and after chemotherapy
in EGFR-positive NSCLC. Induction chemotherapy can induce EGFR expression in
occasional EGFR-negative tumors.
J Clin Oncol 22:4966-4970. © 2004 by American Society of Clinical Oncology
INTRODUCTION
The epidermal growth factor receptor
(EGFR) is expressed in 40% to 80% of non–
small-cell lung cancers (NSCLC), and ex-
pression has been associated with a poor
prognosis.1-3 Because the EGFR signaling
pathway is thought to play a critical role in
the growth and proliferation of NSCLC,
EGFR was identified as an important tar-
get for drug development. New molecules
have been designed to specifically target
either the kinase domain or the interac-
tion with its ligand.
The efficacy of this clinical approach
was shown by data on the antitumor activity
of gefitinib (Iressa [ZD1839]; AstraZeneca,
Wilmington, DE), an orally active EGFR
tyrosine kinase inhibitor, in patients with
advanced NSCLC. In two phase II trials,
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Iressa Dose Evaluation in Advanced Lung Cancer (IDEAL)
1 and IDEAL 2, gefitinib was given at the daily oral dose of
250 or 500 mg to 426 patients with advanced NSCLC pre-
viously treated with systemic chemotherapy. An objective
tumor response rate of 10% to 19%, with a disease control
rate of 42.2% to 54.4%, was observed.4-6
At present, no biomarker has been identified that is
predictive of response to gefitinib. In preclinical studies,
expression of EGFR was not an absolute requirement for
tumor growth inhibition.7,8 An analysis of EGFR mem-
brane staining has been conducted in IDEAL 1 and 2 and
has shown no evidence for a consistent relationship be-
tween EGFR expression levels and tumor response to ge-
fitinib.9 Similar results have been reported from the Iressa
Expanded Access Program.10
To fully evaluate the correlation between EGFR status
and response to gefitinib, it is necessary to know whether
prior systemic chemotherapy could have changed the EGFR
expression. Usually, the sequence of events in treating pa-
tients with advanced NSCLC is to first biopsy the tumor,
then administer the chemotherapy regimen, and after, if
indicated, gefitinib. Therefore, if chemotherapy can change
EGFR expression, then the assessment of EGFR expression
on tissue specimens collected at the time of diagnosis could
be unreliable for predicting gefitinib response. Further,
there are almost no data that compare EGFR status in nodes
paired with primary lung tumors, an essential tool for ana-
lyzing the gefitinib data.
In this study, EGFR expression was evaluated in speci-
mens collected at the time of diagnosis by mediastinoscopy
or mediastinostomy in patients with stage IIIa/b pN2/3
NSCLC and compared with EGFR expression on both




The pathology specimens from 164 consecutive patients with
clinical stage IIIa/b N2/3 were retrieved from the files of the
Divisions of Pathology and Laboratory Medicine and Thoracic
Surgery of the European Institute of Oncology of Milan between
1998 and 2002. New sections were cut for immunohistochemical
analysis and original hematoxylin and eosin sections were re-
viewed; 138 lymph node specimens were tumor-positive and were
analyzed for EGFR status.
Fifty-four patients underwent surgery for cancer resection
after an induction chemotherapy regimen along with a complete
mediastinal lymph node dissection to ensure accurate pathologic
staging. Selection criteria for surgery were N2 nonbulky disease,
no disease progression with induction chemotherapy, patient
preference, and medical conditions precluding surgery. For the
immunohistochemical study, paraffin blocks were retrieved and
original hematoxylin and eosin–stained sections were reviewed.
Immunohistochemical Procedures
Mediastinal lymph nodes assessed for EGFR immunoreactiv-
ity after chemotherapy belonged to the same anatomic site as
sampled during mediastinoscopy to have the most homogeneous
histologic comparison of tumors. If metastatic lymph nodes in the
same site were unavailable for evaluation, other pN1 or pN2
samples were chosen with the largest deposits of tumor cells. There
were no significant differences in the size of analyzed lymph node
fragments obtained before chemotherapy (mean  standard de-
viation [SD], 1.07 0.41 cm; median, 0.9 cm) by mediastinoscopy
and after surgery (mean  SD, 1.16  0.34 cm; median 1) by
sampling the same or similar mediastinal lymph node station.
Moreover, both specimen types were comparable in terms of
neoplastic cellularity, the latter being at least 60% in all tumor
samples under evaluation. Primary lung tumors of resected spec-
imens were entirely immunostained for EGFR if they were 2 cm
in size, whereas at least two representative tissue blocks were
evaluated in larger neoplasms. There were six tumors (five adeno-
carcinomas and one squamous cell carcinoma) measuring 2 cm
in diameter, with the remaining ones measuring greater than 2 cm.
Ten samples of nonneoplastic pulmonary parenchyma and bron-
chial tree at different levels, as well as peritumoral parenchyma
from a representative group of 30 patients with NSCLC (18%)
matched for confounding factors (age, sex, and smoking habit),
were also assessed for EGFR immunoreactivity as noncarcinoma
and carcinoma control groups, respectively.
In all samples, 4 micro-thin paraffin sections were incubated
for 5 minutes at 37°C in 0.1% pronase solution in phosphate
buffer saline 0.01 mol/L at pH 7.4, reacted with a commercially
available mouse monoclonal antibody recognizing the peptide
backbone of the extracellular domain of the EGFR molecule (clone
31G7; DBA, Milan, Italy) at a 50 L/mL dilution for 1 hour at
room temperature, and then incubated with a detection kit (Dako
EnVision Plus-HRP; Dako, Glostrup, Denmark) according to the
manufacturer’s instructions. Peroxidase activity was developed
with 3-3-diaminobenzidine-copper sulfate (Sigma Chemical Co,
St Louis, MO) to obtain a brown-black end product. The specific-
ity of all immunoreactions was double-checked by substituting the
primary antibody with a nonrelated mouse monoclonal antibody
at a comparable dilution and with normal serum alone. Appropri-
ate external positive controls were stained in parallel for each batch
to ensure the overall immunoreactivity quality.
Scoring System for Immunohistochemistry
The slides were assessed for EGFR by one observer experi-
enced in pulmonary pathology (G.P.) and unaware of patient
identity. In all cases, the intensity (weak, moderate, or strong) and
pattern (incomplete or complete) of membrane labeling and the
percentage of immunoreactive neoplastic cells (by scanning at
least 1,000 tumor cells in representative fields of immunostaining)
were accurately recorded. Only the membrane labeling was taken
into account with a 10% threshold for positivity, whereas cytoplas-
mic immunoreactivity was completely disregarded. Combining
intensity and membrane pattern of tumor cells, a four-tier score
(0 to 3) was thus reached for each case, according to the Dako
system formerly used for the HercepTest (DAKO, Carpinteria,
CA). Tumors were considered negative (score 0) if cell membrane
staining was completely absent or positive in up to 10% tumor
cells, whereas a faintly appreciable and incomplete pattern, a
weak-to-moderate but complete staining, or a strong and com-
plete labeling of the membrane in more than 10% tumor cells were
given the threshold of 1, 2, or 3 scores, respectively. A
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known-positive control case (NSCLC comparable in terms of
fixation time and processing and overexpressing EGFR) was in-
cluded in each run of staining and consistently showed the ex-
pected immunoreactivity.
Statistical Analysis
Expression of EGFR was recorded as an ordinal variable
varying from 0 (no expression) to 3. Expression was also codi-
fied as negative or positive by regrouping into a single level all
positive-expressing specimens independently of degree of expres-
sion. Proportion of nodal and/or tumor samples showing level-
specific EGFR expression at diagnosis and after chemotherapy
were provided with accompanying 95% exact binomial confi-
dence limits. Agreement in EGFR expression between specimens
before and after chemotherapy was evaluated using the Goodman
and Kruskal  statistic. When treating agreement as a two-level
variable, agreement was assessed using the kappa statistic. Agree-
ment was considered statistically significant if the P value associated
with the corresponding estimate was  .05. Calculations were done
using StatXact (Cytel Software Corp, Cambridge, MA).
RESULTS
Patients
Specimens collected by 164 consecutive mediastinos-
copies or mediastinostomies performed at the time of
NSCLC diagnosis were evaluated for this analysis. EGFR
status was assessed in 138 of 164 cases; in other 26 patients,
the lymph node samples were either completely negative
for tumor colonization or showed an insufficient number of
tumor cells for a reliable semiquantitative evaluation.
Patient age ranged from 17 to 85 years (mean  SD,
60.3 11.1 years; median, 62 years).
Using the last WHO classification of lung tumors
(1999), 51% of tumors were classified as adenocarcinomas,
40% were classified as squamous cell carcinomas, and 9%
were classified as large-cell carcinomas.
EGFR expression was also evaluated in 47 tumors and
48 involved mediastinal nodes of 54 of 164 patients selected
for surgery after induction chemotherapy (the remaining
specimens showed no tumor or inadequate sample size).
No attempt was made to obtain further biopsy samples
from patients who did not undergo surgery.
EGFR Immunoreactivity in Normal Lung Tissue
All samples of normal pulmonary parenchyma and
bronchial tree from patients with nonmalignant lung dis-
eases and the non-neoplastic peritumoral lung tissue from
the study patients were consistently unreactive for EGFR
antibody. However, a barely appreciable to faint immuno-
reactivity was sometimes encountered in the basolateral
layer of cell membrane of the normal bronchial epithelium
( 10% of examined cells).
EGFR Status at the Time of Diagnosis
In all, 138 cases of involved mediastinal nodes were
stained for EGFR status. EGFR score was 0, 1, 2, and
3 in 22 (16%), 27 (20%), 28 (20%), and 61 (44%) of
cases, respectively.
EGFR Status After Chemotherapy
Patients with absence of EGFR expression at the time of
diagnosis. Twenty-two patients showed no EGFR immu-
noreactivity on specimens collected by pretreatment medi-
astinoscopy or mediastinostomy. Six of them underwent
surgery after chemotherapy. Tumor histotypes were adeno-
carcinoma (three patients), squamous cell carcinoma (one
patient), undifferentiated NSCLC (one patient), and large-
cell carcinoma (one patient).
In all, EGFR changed to a positive status in four pa-
tients (66%) on mediastinal nodes (1 in one case, 2 in
one case, and 3 in two cases) and in three of five primary
tumors (one tumor specimen was not available; Tables 1
and 2). Histotypes of tumors that changed to a positive
EGFR status included adenocarcinoma (two patients),
squamous cell carcinoma (one patient), and large-cell car-
cinoma (one patient). Response to induction chemother-
apy was partial response and stable disease in three and one
patient, respectively. Two cases (one partial response and
one stable disease to induction chemotherapy) remained
EGFR-negative, both on nodes and tumors.
Patients with EGFR score 1 at the time of diagnosis.
Twenty-seven patients showed EGFR score 1 on speci-
mens collected by pretreatment mediastinoscopy or medi-
astinostomy. Seven patients underwent surgery after
induction chemotherapy; all had residual disease at the
primary site at thoracotomy and four had residual tumor in
mediastinal nodes.
One of these seven cases changed to zero EGFR
immunoreactivity both on tumor and nodes. EGFR score
of the remaining six primitive tumors was 1 (two pa-
tients), 2 (two patients), and 3 (two patients) and on
nodes was 1 (two patients), 2 (one patient), and not
assessable in three patients (specimens not available, two
patients; ypN0, one patient; Tables 1 and 2).
Patients with EGFR score 2/3 at the time of diagnosis.
Eighty-nine patients showed EGFR score 2/3 on
specimens collected by pretreatment mediastinoscopy or
Table 1. Epidermal Growth Factor Receptor Status on Mediastinal
Nodes at Diagnosis and After Induction Chemotherapy





EGFR Status After Induction
Chemotherapy (No. of patients)
0 1 2 3 NA
0 6 2 1 1 2 0
1 7 1 2 1 0 3
2 8 0 1 5 2 0
3 26 0 0 7 11 8
Abbreviations: EGFR, epidermal growth factor receptor; NA, not assessable.
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mediastinostomy. Thirty-four underwent surgery after
induction chemotherapy, all but one with residual tumor
in mediastinal nodes and tumor (one patient had ypN0
ypTx disease).
None of these cases changed to zero EGFR immunore-
activity. Four patients showed a minimal score (nodes or
tumor) of 1, the other 29 patients (88%) maintained a
minimal score of 2 (13 patients) or 3 (16 patients;
Tables 1 and 2).
Agreement of EGFR Status in Nodes and Tumor
After Chemotherapy
The score of EGFR status in residual mediastinal nodes
metastases was assessable in 48 of 164 patients who under-
went surgery who had residual tumor in nodes after induc-
tion chemotherapy, and the score in the corresponding
tumors was evaluated in 47 of 48 patients (one patient had
pT0 disease).
In all, the score in the nodes was zero in three patients,
1 in seven patients, 2 in 17 patients, and 3 in 21
patients. Analyzing the subgroup of patients with nodes
scoring 2/3, there was an agreement in the tumor score
in 34 (92%) of 37 patients. The EGFR score in the remaining
three patients was zero (one patient) and 1 (two patients).
One patient was excluded because of a complete pathologic
tumor response.
Analyzing the subgroup of patients with tumor score
2/3 (38 patients), there was an agreement in the nodes
score in 34 (89%) of 38 patients. No cases showed the
absence of EGFR expression, with the four remaining cases
showing a score of 1.
All the cases with absence of EGFR in mediastinal
nodes (three patients) showed zero EGFR expression on the
corresponding tumors. Conversely, three of five tumors
with EGFR score of zero showed an agreement on nodes
(remaining two cases, EGFR score of 1 and 2).
Statistical Analysis
Mediastinal nodes. Taking into account the ordinal
nature of EGFR expression assigned by the pathologist in
mediastinal node specimens obtained at diagnosis, an asso-
ciation was found with EGFR expression in corresponding
nodes sampled during surgery after induction chemother-
apy (  0.66; 95% CI, 0.35 to 0.96; two-sided associated
P .0008). These results indicate good agreement in EGFR
expression between specimens collected at diagnosis and
after treatment in those patients with available paired spec-
imens. When grouping mediastinal node specimens with
positive EGFR expression into a single category, we ob-
served that the vast majority had corresponding postche-
motherapy node specimens with positive EGFR expression
(29 of 30 or 96.7%; 95% exact CI, 82.8% to 99.9%). If, on
the other hand, agreement is assessed, a kappa statistic of
0.375 is obtained (two-sided associated P .015), indicat-
ing moderate agreement that is probably due to the discor-
dance in the negative expressing specimens.
Tumor. An association was found between the degree
of expression in mediastinal nodes sampled at diagnosis and
EGFR expression in corresponding primary tumor tissue
collected after induction chemotherapy (gamma  0.51;
95% CI, 0.18 to 0.84; two-sided associated P .01).
When evaluating EGFR expression as a two-level vari-
able, the overwhelming majority of specimens showing
positive expression at diagnosis had corresponding post-
chemotherapy primary tumor specimens with positive
EGFR expression (35 of 36 or 97.2%; 95% exact CI, 85%
to 99.9%). Assessing agreement, a kappa statistic of 0.449
was obtained (two-sided associated P  .0027), indicat-
ing moderate agreement.
DISCUSSION
This study was performed to assess whether EGFR status
could be modulated by chemotherapy in patients with lo-
cally advanced NSCLC selected for surgery and to evaluate
the agreement of EGFR expression between the primary
tumor and mediastinal node metastases.
The incidence of EGFR positive status in this selected
population of 138 patients with locally advanced NSCLC
was 84%, which is consistent with the rate of expression
reported by others in NSCLC.1-3
Our results suggest a very good overall agreement
of EGFR status before and after systemic chemotherapy in
EGFR-positive tumors. Overall, only one of 41 EGFR-positive
tumors at diagnosis changed to EGFR-negative immunoreac-
tivity after chemotherapy. This case scored 1 at diagnosis.
This observation suggests that a rebiopsy in an EGFR-
positive patient after chemotherapy to reassess EGFR status
is not necessary. Moreover, those observations support the
methodologic adequacy of the ongoing retrospective anal-
ysis of the relationship between EGFR expression and re-
sponse to gefitinib for EGFR-positive patients treated in
studies such as IDEAL 1 and IDEAL 2.4,5 In these studies,
according to the inclusion criteria, all patients treated with
gefitinib were pretreated with systemic chemotherapy after
Table 2. Epidermal Growth Factor Receptor Status on Mediastinal
Nodes at Diagnosis and on Primitive Tumor After Induction





EGFR Status After Induction
Chemotherapy (No. of patients)
0 1 2 3 NA
0 6 2 0 1 2 1
1 7 1 2 2 2 0
2 8 0 2 3 2 1
3 26 0 2 5 15 4
Abbreviations: EGFR, epidermal growth factor receptor; NA, not assessable.
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diagnosis. If chemotherapy has been shown to change
EGFR status, all specimens collected at diagnosis would
need to be ignored in correlative studies linking EGFR expres-
sion to response to gefitinib. Our data suggest that chemother-
apy does not change EGFR-positive status significantly.
Our study also suggests that induction chemotherapy
can induce EGFR expression in occasional patients with
EGFR-negative tumors. The observation of this switch is
consistent with the hypothesis that the EGFR ligand could
be used as a survival factor to rescue from chemotherapy-
induced damage.11,12
As a consequence, whenever the knowledge of EGFR
status is useful for proper decision making in patients
with EGFR-negative NSCLC treated with chemotherapy,
a postchemotherapy rebiopsy to assess EGFR expression
is recommended.
According to our data, no difference would be expected
if biopsy is performed on the primary tumor or on medias-
tinal nodes. In this study, the analysis of the EGFR score
assessed on residual mediastinal nodes at the time of surgery
showed an agreement in the corresponding primary tumors
of 92% and 100% in patients with a score of 2/3 and
score of zero, respectively.
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